OVERVIEW OF ACTIVITY
Prostate cancer is the most frequently diagnosed cancer in men, with an estimated 220,000 new cases and approximately 60,000 patients becoming resistant to castration levels of testosterone in the United States every year. Recently published randomized controlled studies have led to the emergence of novel therapeutic strategies for patients with castration-resistant prostate cancer. The treatment landscape and available options for prostate cancer have thus broadened, making choices more challenging for many healthcare professionals and patients despite the recent gains made in the management of this disease. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. Oncology clinicians must possess a clear understanding of the benefits and risks of each of the various available options and how best to integrate the emerging data and new agents into the therapeutic algorithm. To bridge the gap between research and patient care, this activity is designed to expose oncology clinicians to peer-reviewed evidence and expert perspectives that can be translated into strategies for optimal patient care.
LEARNING OBJECTIVES
- Assess the efficacy and safety of radiation therapy after radical prostatectomy for patients with high-risk early-stage prostate cancer.
- Optimize the management of asymptomatic, mildly symptomatic or symptomatic castration-resistant prostate cancer (CRPC) through rational integration of prospective Phase III data.
- Communicate the benefits and risks of taxane-based chemotherapy regimens to patients with newly diagnosed or recurrent CRPC.
- Use clinical risk factors and tests to identify patients at risk for developing skeletal fractures, and develop a management approach to preserve bone health.
- Summarize emerging efficacy and safety data with targeted agents in CRPC, including microtubule stabilizers, endothelin A receptor antagonists, cellular immunotherapy and novel inhibitors of testosterone synthesis or activity.
- Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. To receive credit, the participant should listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/PCUTT110/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Dreicer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Centocor Ortho Biotech Services LLC, EMD Serono Inc, Millennium Pharmaceuticals Inc; Speakers Bureau: Sanofi-Aventis. Dr Freedland — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Myriad Genetics Inc; Consulting Agreement: Amgen Inc; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc. Dr Kantoff — Advisory Committee: Amgen Inc, Millennium Pharmaceuticals Inc, Pfizer Inc. Dr Moul — Advisory Committee: AstraZeneca Pharmaceuticals LP, Ferring, GlaxoSmithKline; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP; Speakers Bureau: Aureon Laboratories Inc, Ferring, Sanofi-Aventis. Dr Sandler — Advisory Committee: Genentech BioOncology; Consulting Agreements: Calypso, Centocor Ortho Biotech Services LLC, Varian Medical Systems Inc; Stock Ownership: Biogen Idec. Dr Sartor — Advisory Committee: Bristol-Myers Squibb Company, GlaxoSmithKline; Consulting Agreements: Algeta ASA, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Corporation, GlaxoSmithKline, GPC Biotech, Johnson & Johnson Pharmaceuticals, Medivation, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis; Paid Research: Algeta ASA, AstraZeneca Pharmaceuticals LP, Cougar Biotechnology Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Sanofi-Aventis; Speakers Bureau: EUSA Pharma. Dr Smith — Consulting Agreement: Amgen Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Dendreon Corporation, Millennium Pharmaceuticals Inc and Sanofi-Aventis.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: January 2011
Expiration date: January 2012
